The dangers imposed by O2 arise from its electronic structure. It contains two unpaired electrons with parallel spin states, located on the second sheet (L), concretely on 2py and 2pz orbitals. Electrons tend to distribute according to a minimal repulsion, and two electrons with the same spin repel each other with more intensity than when their spins are antiparallel. For these reasons, if O2 is in contact with a reductant molecule, electrons are transferred to O2 one at a time: the first occupies the 2py orbital and the second occupies the 2pz orbital. The first step gives the superoxide ion (O2 ·–), and the second step (linked to the transfer of 2H+) gives hydrogen peroxide (H2O2). Two more electrons are needed to reduce O2 to two molecules of water (Fig. 16.1). Hence this univalent pathway usually needs intermediates, and those intermediates include strongly oxidant reactive oxygen species such as superoxide ions and hydroxyl radicals.
References
Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in postmortem substantia nigra of parkinsonian brain. J Neural Trans 1988;74, 199–205.
Morris CM, Edwardson JA. Iron histochemistry of the substantia nigra in Parkinson’s disease. Neurodegeneration 1994; 3, 277–82.
Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87, 1620–24.
Reif DW, Simmons RD. Nitric oxide mediates iron release from ferritin. Arch Biochem Biophys 1990, 283: 537–41.
Hirsch EC, Mouatt A, Faucheux B, et al. Dopamine, tremor, and Parkinson's disease. Lancet 1992;340(8811):125–6.
Shapira AHV, Cooper JM, Dexter D. Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1989; 1:1269.
Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson’s disease. J Neural Transm 1997;104: 661–77.
Hunot S, Boissiere F, Faucheux B, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease. Neuroscience 1996; 72, 355–63.
Bolanos JP, Almeida A, Stewart V et al. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J Neurochem 1997, 68: 2227–40.
Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A. 1996, 93:4565–71.
Liberatore GT, Jackson-Lewis V, Vukosavic S, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999, 5(12):1403–9.
Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of a meperidine-analog synthesis. Science 1983;219, 979–80.
Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 1998;70, 2682–75.
Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 1989;52:381–9.
Yoritaka A, Hattori N, Uchida K, et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 1996; 93(7):2696–701.
Picklo MJ, Amarnath V, McIntyre JO, Graham DG, Montine TJ. 4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites. J Neurochem 1999; 72(4):1617–24.
Meyer MJ, Mosely DE, Amarnath V, Picklo MJ Sr. Metabolism of 4-hydroxy-trans-2-nonenal by central nervous system mitochondria is dependent on age and NAD+ availability. Chem Res Toxicol 2004;17(9):1272–9.
Alam Z.I., Zenner A., Daniel S.A., Lees A.J., Caims N., Marsdem C.D., Jenner P., and Haliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997;69:1196–203.
Bucciantini M, Giannoni E, Chiti F, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002;416:507–11.
Hurtig HI, Trojanowski JQ, Galvin J, et al. α-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 2000; 54:1916–21.
Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P. Effect of mutant α-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem 2002; 277:38884–94.
Shermann MY, Goldberg A. Involvement of molecular chaperones in intracellular protein breakdown. EXS 1996;77:57–78.
McNaught KSP, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci. Lett 2002; 326:150–158.
Zhang J, Perry G, Smith MA, et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 1999;154(5):1423–9.
Hartley A, Cooper JM, Shapira AH. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson’s disease. Brain Res 1993; 627: 349–53.
Hasegawa E, Takeshige K, Oishi T, et al. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun 1990; 170: 1049–1055.
Hartley A, Stone JM, Heron C, Cooper JM, Schapira AH. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 1994; 63(5):1987–90.
Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol 2003; 53: S26–S38.
Ben-Schachar D, Zuk R, Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 1995; 64: 718–723.
Merad-Boudia M, Nicole A, Santiard-Baron D, Saillé C, Ceballos-Picot I. Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease. Biochem Pharmacol 1998; 56(5):645–655.
Stokes AH, Hastings TG, Vrana KE. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 1999; 55(6):659–65.
Velez-Pardo C, Jimenez Del Rio M, Verschueren H, Ebinger G, Vauquelin G. Dopamine and iron induce apoptosis in PC12 cells. Pharmacol Toxicol 1997; 80(2):76–84.
Olney JW, Ho OL. Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine. Nature 1970; 227: 609–611.
Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdyalisis. J Neurochem 1984, 43:1369–74.
Pellegrini-Giampietro DE, Gorter JA, Bennett MV, Zukin RS. The GluR2 (GluR-B) hypothesis: a Ca2+-permeable AMPA receptors in neurological disorders. Trens Neurosci 1997; 20:464–70.
Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson’s disease. J Neural Trans 2000; 60: 277–90.
Hunot S, Vila M, Teismann P, et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A. 2004; 101(2):665–70.
Vawter MP, Dillon-Carter O, Tourtellotte WW, Carvey P, Freed WJ. TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson’s disease in ventricular cerebrospinal fluid. Exp Neurol 1996; 142: 313–322.
Nagatsu T, Sawada M. Cellular and molecular mechanisms of Parkinson’s disease: Neurotoxins, Causative Genes, and Inflammatory Cytokines. Cell Mol Neurobiol 2006; 26: 781–802.
Hunot S., Hirsch E.C. Neuroinflammatory processes in Parkinson’s disease. Ann Neurol 2003; 53 (suppl 3):S49–S60.
Hunot S, Dugas N, Faucheux B, et al. FcεRII/CD23 is expressed in Parkinson’s disease and induces, in vitro, production of nitric oxide and tumor necrosis-alpha in glial cells. J Neurosci 1999; 19:3440–7.
McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLD-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 1988; 38: 1285–1291.
Rowe DB, Le W, Smith RG, Appel SH. Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. J Neurosci Res 1998; 53(5):551–558.
Höglinger GU, Breunig JJ, Depboylu C, et al. The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl Acad Sci USA. 2007; 104(9):3585–90.
Fernandez-Espejo E. Pathogenesis of Parkinson’s disease: prospects of neuroprotective and restorative therapies. Mol Neurobiol 2004; 9:15–30.
Acknowledgments
This study was supported by grants to EFE from Junta de Andalucia, Spain (BIO127, and Proyectos de Excelencia, EXC/2006/CVI127-1716), and Red de Tera (Instituto Carlos III, RD06/025).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Fernández-Espejo, E. (2009). Pathogenesis of Oxidative Stress and the Destructive Cycle in the Substantia Nigra in Parkinson’s Disease. In: Tseng, KY. (eds) Cortico-Subcortical Dynamics in Parkinson's Disease. Contemporary Neuroscience. Humana Press. https://doi.org/10.1007/978-1-60327-252-0_16
Download citation
DOI: https://doi.org/10.1007/978-1-60327-252-0_16
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-251-3
Online ISBN: 978-1-60327-252-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)